Back

Cardiopulmonary exercise test findings are not the same in distinct types of cardiac amyloidosis.

31 August 2024 (17:00 - 17:50)
Organised by: Logo
Congress Presentation Part of: Exercise testing in different pathological conditions Exercise Testing ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speakers

Photo
Doctor Sebastian Santos Patarroyo

Rochester (United States of America)

Photo
Doctor Laura Melissa Ortega Aviles

Rochester (United States of America)

7 More presentations in this session

Presentation thumbnail
The ventilatory efficiency parameters outperform peak oxygen consumption in monitoring the therapy effects on the right ventricular load in patients with hypertrophic cardiomyopathy
Doctor L. Mikic (Belgrade, RS)
Abstract Slides Video
Presentation thumbnail
Disability in activities of daily living before hospitalisation and clinical outcomes following acute-phase rehabilitation in older individuals with cardiovascular disease
Doctor N. Hamazaki (Sagamihara, JP)
Abstract Slides Video
Presentation thumbnail
The optimal cut-off value for the one-minute sit-to-stand test to determine functional impairment in patients with pulmonary hypertension
Doctor C. Kronberger (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
What is the true normal: comparison of different equations for estimating peak oxygen uptake for outcome prediction in heart failure
Doctor R. Amador (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Exercise oscillatory ventilation as a predictor of mortality in patients with amyloid cardiomyopathy
Doctor R. Willixhofer (Milan, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Exercise testing in different pathological conditions

The Event

Event poster

ESC Congress 2024

31 August 2024 17:00 CET
You may be interested in
thumbnail
Congress Presentation
Transthyretin amyloid cardiomyopathy (ATTR-CM): a potential role for cardiopulmonary exercise testing
thumbnail
Congress Presentation
Cardiopulmonary exercise testing as a novel endpoint in clinical trials on ATTR amyloid cardiomyopathy
thumbnail
Congress Presentation
The role of CPET for the assessment of patients with transthyretin amyloid cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources